NEW YORK (GenomeWeb News) – Flagship Biosciences today announced a partnership with PrognosDx Health to provide pharmaceutical firms and cancer centers access to tissue-based, global patterns of histone modification patient profiling.
The services will be used in early-stage drug discovery and clinical trials, Flagship said in a statement.
PrognosDx is an early-stage epigenetics firm with "unique global patterns of histone modification patient profiling technology," it said. Flagship provides digital pathology services.
The two companies will share profits arising from their partnership, which is primarily based on providing laboratory-based testing services, to be launched during the current quarter. Further financial details of the deal were not disclosed.
The testing services will initially focus on testing of specimens associated with pharma therapeutic oncology programs "where global patterns of histone modification patient profiling may identify sub-population of the patients who will be the likely responders to the drugs in development," Flagship said.
The services may also be applied to animal studies, target identification, target validation, and efficacy studies, particularly for HDACi class of compounds, various pro-drugs, some chemotherapeutics, compounds inhibiting the nucleotide synthesis process, and compounds that impact certain proprietary metabolic pathways, they added.
Based in Palo Alto, Calif., PrognosDx's epigenetic technology is based on the predictive power of global histone modification patterns and is licensed from the University of California, Los Angeles. Flagship is based in Flagstaff, Ariz.